Spyre Therapeutics Inc (SYRE)

03:32 AM

Spyre Therapeutics Inc. Bounces Off Moving Average SupportJuly 2025 Momentum & Detailed Earnings Play Strategies - 선데이타임즈

03:32 AM

07:36 AM

Spyre Therapeutics Inc.’s volatility index tracking explainedMarket Movers & Fast Gain Swing Trade Alerts - Newser

07:36 AM

06:37 AM

When is the best time to exit Spyre Therapeutics Inc.2025 Dividend Review & Fast Gaining Stock Strategy Reports - Newser

06:37 AM

04:01 AM

Will Spyre Therapeutics Inc. bounce back from current supportEarnings Risk Report & Daily Oversold Stock Bounce Ideas - Newser

04:01 AM

02:37 AM

Is now a turning point for Spyre Therapeutics Inc.Quarterly Portfolio Report & Low Volatility Stock Recommendations - Newser

02:37 AM

01:34 AM

Is Spyre Therapeutics Inc. forming a bottoming baseShort Setup & Fast Gain Stock Trading Tips - Newser

01:34 AM

Aug 13, 2025

What moving averages say about Spyre Therapeutics Inc.2025 Risk Factors & Daily Stock Trend Watchlist - Newser

Aug 13, 2025

Aug 13, 2025

Spyre Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - Newser

Aug 13, 2025

Aug 13, 2025

Is it time to cut losses on Spyre Therapeutics Inc.Recession Risk & Weekly Momentum Stock Picks - Newser

Aug 13, 2025

Aug 13, 2025

Real time scanner hits for Spyre Therapeutics Inc. explainedEarnings Growth Report & Risk Managed Investment Entry Signals - Newser

Aug 13, 2025

Aug 13, 2025

Natixis Advisors LLC Has $265,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Aug 13, 2025

Aug 12, 2025

Using flow based indicators on Spyre Therapeutics Inc.Daily Trade Monitor with Pattern Alerts - Newser

Aug 12, 2025

Aug 12, 2025

Will Spyre Therapeutics Inc. rebound enough to break evenPrice Spike Prediction for Active Traders - Newser

Aug 12, 2025

Aug 12, 2025

Combining machine learning predictions for Spyre Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser

Aug 12, 2025

Aug 12, 2025

Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsChart Signal and Short-Term Forecast Tracker - Newser

Aug 12, 2025

Aug 12, 2025

What institutional flow reveals about Spyre Therapeutics Inc.Short-Term Profit Alert With Entry Forecast - Newser

Aug 12, 2025

Aug 12, 2025

Using AI based signals to follow Spyre Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser

Aug 12, 2025

Aug 11, 2025

How Spyre Therapeutics Inc. stock performs during market volatilityFree Low Risk High Return Opportunities - Newser

Aug 11, 2025

Aug 11, 2025

What data driven models say about Spyre Therapeutics Inc.’s futureFree AI Driven Buy Alert Trade Blueprint - Newser

Aug 11, 2025

Aug 11, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Aug 11, 2025

Aug 11, 2025

What’s the recovery path for long term holders of Spyre Therapeutics Inc.Daily Trade Setup Forecast with Confidence - Newser

Aug 11, 2025

Aug 11, 2025

Spyre Therapeutics Inc. Consolidation Zone May Signal AccumulationBreakout Momentum Picks With Protection Outlined - beatles.ru

Aug 11, 2025

Aug 10, 2025

Will a bounce in Spyre Therapeutics Inc. offer an exitChart Confirmation Setup with ROI Signals - Newser

Aug 10, 2025

Aug 09, 2025

Why Spyre Therapeutics Inc. stock attracts strong analyst attentionWeekly Growth Portfolio Performance Summary - Newser

Aug 09, 2025

Aug 09, 2025

Applying sector rotation models to Spyre Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser

Aug 09, 2025

Aug 09, 2025

Can Spyre Therapeutics Inc. expand its profit marginsFree Trading Community Access - thegnnews.com

Aug 09, 2025

Aug 09, 2025

Can momentum traders help lift Spyre Therapeutics Inc.Free Weekly Chart Analysis With Entry Advice - Newser

Aug 09, 2025

Aug 06, 2025

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows - Nasdaq

Aug 06, 2025

Aug 06, 2025

Stifel reiterates Buy rating on Spyre stock with $71 price target - Investing.com Canada

Aug 06, 2025

Aug 06, 2025

Spyre Therapeutics: Q2 Earnings Snapshot - New Haven Register

Aug 06, 2025

Aug 06, 2025

Spyre Therapeutics shares fall 5.45% intraday despite positive Phase 1 results and Phase 2 study initiations. - AInvest

Aug 06, 2025